Bernstein Liebhard LLP Attorneys Look Ahead to Litigation Housing Hundreds of Risperdal Lawsuits Filed by the Firm

Share Article

The Firm is looking forward to a status conference on March 19, 2015 that will discuss issues that affect hundreds of Risperdal lawsuit claimants.

Free Case Review
“We anticipate that many important issues relating to the Risperdal litigation will be discussed at this conference. We are eager to report those updates to the hundreds of clients we are representing in Risperdal lawsuits.

Risperdal lawyers (http://www.risperdallawsuit2014.com/) at Bernstein Liebhard LLP are awaiting a status conference scheduled for next week in the Philadelphia Court of Common Pleas, the Firm comments.

The meeting will take place on March 19th, 2015 at 10:30 a.m., at which time counsel for the plaintiffs and defendants will convene to discuss issues related to claims over the antipsychotic medication, which is manufactured by Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals. Claims included in the consolidated litigation, allege symptoms associated with the condition referring to male breast growth, gynecomastia, as well as other complications. (In Re: Risperdal Litigation, Case Number 100300296)

“We anticipate that many important issues relating to the Risperdal litigation will be discussed at this conference. We are eager to report those updates to the hundreds of clients we are representing in Risperdal lawsuits,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently representing hundreds of Risperdal plaintiffs whose claims are pending, and is currently offering free and confidential case reviews to individuals who may be eligible to file cases against Johnson & Johnson and Janssen.

Risperdal Lawsuits

According to court documents, Risperdal lawsuits now filed in Pennsylvania allege Johnson & Johnson and Janssen’s failure to adequately warn about gynecomastia and other risks associated with the medication, which is approved by the U.S. Food and Drug Administration (FDA) to treat schizophrenia and bipolar disorder in adults and adolescents, as well as irritability symptoms related to autism. The drug garnered additional clearance in 2006 for certain pediatric uses. According to Risperdal plaintiffs, Johnson & Johnson and Janssen allegedly promoted the medication to children before this time, as well as for other off-label uses. The companies are also accused of intentionally concealing the findings of research that revealed Risperdal’s potential to raise levels of the hormone, prolactin, which could lead to gynecomastia complications.

Court records indicate that the second bellwether trial in the consolidated Risperdal litigation in the Philadelphia Court of Common Pleas is underway. The case now at trial was filed by a plaintiff who was treated with the medication for oppositional defiant disorder as a child before it was cleared for pediatric uses.* (Case No. 130301803)

The proceeding’s first bellwether trial of a Risperdal gynecomastia lawsuit concluded on February 24th with a $2.5 million damage award to a man who developed substantial male breasts as a child taking Risperdal. (Case No. A-196444)

Risperdal patients who allegedly developed gynecomastia afterward may be eligible to file their own lawsuit against Johnson & Johnson and Janssen. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm’s website, or by calling 800-511-5092.

*pennrecord.com/news/15821-risperdal-pelvic-mesh-suits-cause-spike-in-filings-at-philadelphias-mass-torts-program, Pennsylvania Record, February 19, 2015

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website